Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | YH004 |
Synonyms | |
Therapy Description |
YH004 is an agonistic monoclonal antibody that targets CD137 (4-1BB; TNFRSF9), resulting in increased CD137 signaling and potentially leading to inhibition of T-regulatory cells and induction of a cytotoxic T-lymphocyte (CTL)- and NK cell-mediated antitumor response, resulting in tumor cell killing (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
YH004 | YH 004|YH-004 | TNFRSF9 Antibody 32 | YH004 is an agonistic monoclonal antibody that targets CD137 (4-1BB; TNFRSF9), resulting in increased CD137 signaling and potentially leading to inhibition of T-regulatory cells and induction of a cytotoxic T-lymphocyte (CTL)- and NK cell-mediated antitumor response, resulting in tumor cell killing (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05040932 | Phase I | YH004 | Study of YH004 (4-1BB Agonist Antibody) in Advanced or Metastatic Malignancy | Completed | AUS | 0 |